Home Blog Page 147

Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma

By
Advertorial Desk
-

SHANGHAI, Aug. 28, 2026 /PRNewswire/ — Asieris Pharmaceuticals today released its 2026 Semi-Annual Report, showing comprehensive progress across all business segments. With the gradual realization of commercial launch and international expansion for its core products, the company is accelerating its transition from Biotech to Biopharma: CEVIRA®, the world’s first non-invasive treatment for precancerous cervical lesions[1], has been successfully launched in China, ushering in a new era of non-invasive therapy; its Marketing Authorization Application(MAA) in Europe has been accepted for review by the European Medicines Agency(EMA), marking the first step in internationalization. At the same time, the company’s Commercialization 2.0 strategy is entering a harvest period, driving steady performance growth, while the innovation pipeline is advancing rapidly with multiple key milestones achieved.

Steady Growth in Commercial Performance with Core Drivers Further Strengthened

In the first half of 2026, amid a dynamic external market environment, Asieris successfully launched CEVIRA®, the world’s first non-invasive treatment for precancerous cervical lesions, and steadily advanced its Commercialization 2.0 upgrade, refining its commercial system and improving efficiency. During the reporting period, the company recorded operating revenue of RMB 155 million, up 19.28% year over year. Its breast cancer products Ouyoubi® and Ounalin®, together with kidney cancer product Dipaite®, continued to drive growth through academic engagement and channel expansion, solidifying its commercialization capabilities and laying a foundation for the sales of its core product CEVIRA®.

The company’s core product CEVIRA® received regulatory approval in China in March 2026, becoming the world’s first non-surgical, non-invasive treatment for precancerous cervical lesions and filling a critical clinical gap in this therapeutic area. In just three months, in June 2026, the product achieved its first shipment, with the world’s first prescription issued in Beijing on the same day—fully demonstrating cross-functional collaboration efficiency and commercial supply capabilities. Within 10 days of the initial launch, first prescriptions were rapidly rolled out across 70 hospitals in 30 cities nationwide, with an exclusive online launch on JD Health. To date, the product has been adopted in over 150 hospitals across the country.

Asieris will continue to accelerate the sales ramp-up of CEVIRA®. The company has established a comprehensive omnichannel commercial presence centered on public hospitals, having successfully built a specialized promotion team of more than 100 professionals focused on physician education and clinical evidence dissemination for photodynamic therapy in cervical high-grade squamous intraepithelial lesions (HSIL), spanning medical affairs, marketing, and sales. This is complemented by a full commercial support structure encompassing government affairs and market access, sales excellence operations, commercial operations, supply chain, and compliance. Meanwhile, the company is also leveraging commercial partners to achieve full-territory business coverage in broader markets.

At the same time, the company continues to intensify market education efforts and drive the upgrade of therapeutic paradigms. On the academic front, it is prioritizing post-marketing studies to strengthen clinical data, continuously publishing multidimensional subgroup analysis results in domestic and international journals and at major congresses, and expanding dissemination through national academic platforms. In terms of guideline and consensus updates, two Chinese consensus documents have already been released in the first half of 2026. Notably, in the 2026 updated photodynamic therapy consensus issued by the Chinese Society for Colposcopy and Cervical Pathology (CSCCP), CEVIRA® is recommended, with Level 1A evidence, for the treatment of cervical intraepithelial neoplasia grade 2 (CIN2). During the 19th International Federation for Cervical Pathology and Colposcopy (IFCPC) Congress in June 2026, the company initiated an international expert consensus meeting on the standardized application of local photodynamic therapy (PDT) for precancerous cervical lesions, helping to shape global treatment guidelines.

To address accessibility and financial burden, the company has conducted and published disease burden and pharmacoeconomic studies, and released a Fertility-Friendly Blue Book in July 2026 to maximize market accessibility opportunities. Together with the China Women’s Development Foundation, it has launched the “Fertility-Friendly Cervical Health Care” public benefit program, aimed at reducing unnecessary cervical excision procedures through the establishment of fertility-friendly cervical clinics. Following the successful kickoff meeting in Beijing at the end of 2025, the program has rolled out exchange activities and extensive public education campaigns across multiple provinces, building a fertility-friendly cervical care model while establishing public awareness of proper diagnosis and treatment for precancerous cervical lesions. In addition, the company continues to optimize its production and supply chain system to ensure sustained high-quality product supply.

In urologic oncology, Hexvix®, China’s first approved blue-light imaging agent for bladder cancer, has opened a new era of blue-light diagnosis and treatment for bladder cancer in the country. The SYSTEM BLUE blue-light cystoscopy system, developed by Asieris’ partner R.WOLF, received market approval in April 2026, providing a realistic foundation for the clinical value of the blue-light diagnostic and treatment approach. The company will accelerate the market introduction of Hexvix® in combination with the blue-light cystoscopy system to benefit patients as soon as possible. Meanwhile, to fully advance the integrated full-cycle diagnosis and treatment process for bladder cancer, the company has developed the world’s first portable single-use blue-light flexible cystoscope for diagnostic and surveillance applications in bladder cancer[2]. This product has received EU CE certification and will be further accelerated for market approval in China.

R&D Focused on Core Therapeutic Areas, Accelerating Advancement of High-Potential Programs

Guided by its strategic priorities, Asieris has continued to deepen its focus in core therapeutic areas, optimize resource allocation, and concentrate efforts on high-potential pipeline programs by leveraging its targeted and AI-driven drug discovery platform, drug-device combination platform, and innovative ADC technologies. During the reporting period, multiple pipeline programs achieved positive progress, demonstrating innovative advantages and competitive potential and fully reflecting the company’s R&D strength and clinical development capabilities in its areas of focus.

In women’s health, the core product CEVIRA® has made positive progress in international market development, with its MAA successfully accepted for review by the EMA. The company is actively establishing commercial partnerships in Europe, emerging markets, and Belt and Road countries and regions.

In urologic oncology, the Phase I clinical trial of APL-2401 (FGFR2/3 inhibitor) completed enrollment of the first patient in January 2026, with dose escalation proceeding smoothly and efficiently, and preliminary safety characteristics and efficacy signals observed. APLD-2304 (the world’s first portable single-use blue-light flexible cystoscope) passed review by the EU Notified Body and obtained EU CE certification in August 2026. The company is currently preparing for commercial production and actively exploring overseas commercialization partnership opportunities.

In breast cancer and gynecologic oncology, APL-2501 (CLDN6/9-ADC) submitted IND applications in both China and the U.S. in June and July 2026, respectively, and received FDA and NMPA approval to initiate clinical trials in August, with plans to start a Phase I monotherapy dose-escalation study by year-end enrolling patients with advanced solid tumors including ovarian cancer and non-small cell lung cancer. APL-2302 (USP1 inhibitor) is currently in an ongoing Phase I/IIa clinical trial for the treatment of advanced solid tumors.

In other disease areas, based on positive results from the first stage of the clinical study of APL-1401 for moderate-to-severe active ulcerative colitis (UC), the company has further initiated an extension study to evaluate the potential of this First-in-class therapy in a broader UC patient population over a 12-week treatment period. The clinical study is progressing smoothly, with data readout expected by the end of 2026. Given that APL-1202 has shown initial efficacy for the treatment of free-living amoebae (FLA) infections, the company has signed an investigational drug supply agreement with the U.S. CDC under its Expanded Access Program and obtained authorization under Health Canada’s Special Access Program to ensure access for FLA patients.

Dr. Kevin Pan, Founder, Chairman and CEO of Asieris Pharmaceuticals, said: “In the first half of 2026, Asieris achieved multiple milestones in both commercialization and innovation pipelines. We delivered sustained sales growth and significant pipeline progress. Most excitingly, our core product CEVIRA®—the world’s first non-invasive treatment for precancerous cervical lesions—was successfully launched in China with a strong commercial start, marking the company’s official entry into a phase of accelerated delivery of innovation outcomes and further solidifying the foundation for our transition from Biotech to Biopharma. Looking ahead, we are confident in continuing to achieve breakthroughs through steady growth, bringing more benefits to patients and creating greater value for shareholders and society.”

[1] Insight Database

[2] GlobalData Medical Devices database

Disclaimer:

This document is intended to disclose the company’s latest developments and is not a product promotion advertisement. The relevant information is not intended for patients but is provided solely for the reference of healthcare professionals. If you would like to learn more about these diseases, please consult healthcare professionals. The aforementioned content includes forward-looking statements concerning the company’s future plans and development strategies. These statements do not represent binding commitments by the company to investors. Investors are cautioned to consider investment risks.

 

Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering

By
Advertorial Desk
-

SYDNEY, Aug. 28, 2026 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the “Offering”) of (i) 2,580,000 American Depositary Shares (“ADSs”), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase up to 2,243,478 ADSs (or pre-funded warrants in lieu thereof), which are exercisable immediately at a purchase price of $17.825 per ADS and will expire upon the earlier of 30 days following the Company’s Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or the five-year anniversary of issuance, and (iii) accompanying Series B Warrants to purchase up to 2,064,000 ADSs (or pre-funded warrants in lieu thereof), which are exercisable immediately at a purchase price of $19.375 per ADS and will expire upon the earlier of 30 days following the Company’s HR+/HER2- data readout, expected in the first half of 2028, or the five-year anniversary of issuance. All of the securities in the Offering are being sold by Kazia. The combined public offering price for each ADS and accompanying warrants is $15.50, and the combined public offering price for each pre-funded warrant and accompanying warrants is $15.4999 (equal to the combined public offering price per ADS and accompanying warrants less $0.0001), for expected gross proceeds to Kazia of approximately $40 million, before deducting underwriting discounts and commissions and offering expenses. If all of the Series A Warrants and Series B Warrants are exercised in full, the Company would receive additional gross proceeds of approximately $80 million, before deducting applicable expenses.

Leerink Partners and Guggenheim Securities are acting as joint bookrunning managers for the Offering. BTIG and Needham & Company are acting as lead managers for the Offering. Laidlaw & Company (UK) Ltd. is acting as co-manager for the Offering.

The Offering is expected to close on or about August 31, 2026, subject to satisfaction of customary closing conditions.

Kazia intends to use the net proceeds from the Offering primarily to fund clinical development of paxalisib, including ongoing and planned studies in triple-negative breast cancer and HR+/HER2- breast cancer and other oncology indications, and for working capital and general corporate purposes.

The ADSs and warrants are being offered pursuant to a registration statement on Form F-3 (File No. 333-294392), which was previously filed with and subsequently declared effective by the Securities and Exchange Commission (the “SEC”). The Offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Additionally, electronic copies of the preliminary prospectus supplement and the accompanying base prospectus may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com, or from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: (212) 518-9544, email: GSEquityProspectusDelivery@guggenheimsecurities.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the Offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Kazia Therapeutics

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. The Company’s lead asset, paxalisib, is an investigational brain penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of over 15 clinical trials. A completed Phase 2/3 study in glioblastoma (GBM AGILE) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval.

Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy.

Additionally, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020 and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially first-in-class SETDB1 inhibitor program intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Both programs are currently in preclinical development.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding the Offering and the potential gross proceeds therefrom, including the exercise of the Series A Warrants and Series B Warrants; the Company’s ability to achieve clinical milestones, including the Stage IV TNBC and HR+/HER2- data readouts that may trigger warrant exercise periods; the Company’s intended use of proceeds; and the Company’s plans for clinical development of paxalisib. Forward-looking statements are generally identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “may,” “will,” “could,” “should,” “estimates,” “projects,” “potential,” and similar expressions. These forward-looking statements are based on management’s current expectations and assumptions as of the date of this press release and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied.

Such risks and uncertainties include, but are not limited to: the Company’s ability to complete the Offering; the Company’s ability to achieve clinical milestones, including the Stage IV TNBC and HR+/HER2- data readouts that trigger warrant exercise periods; risks associated with the conduct of clinical trials and regulatory approvals; volatility in the price of the Company’s ADSs and warrants; general economic and market conditions; and the Company’s ability to maintain compliance with NASDAQ listing requirements.

For a more complete discussion of risks and uncertainties, please refer to the Company’s filings with the SEC, including the “Risk Factors” section of the Company’s most recent Annual Report on Form 20-F. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements are qualified in their entirety by this cautionary statement.

 

Why Helsinki Should Be on Every Art Lover’s Travel List in Summer 2027

By
Advertorial Desk
-

HELSINKI, Aug. 28, 2026 /PRNewswire/ — Following a record-breaking edition that attracted more than half a million visits, Helsinki Biennial returns in summer 2027, inviting visitors to discover world-class contemporary art across the historic island of Vallisaari, Esplanade park and HAM Helsinki Art Museum. The biennial has now revealed its theme, Unknowns, and announced the first 12 participating artists.

Helsinki Biennial combines world-class contemporary art with nature, maritime landscapes and vibrant city life in a way that is distinctly Helsinki. Located just a short ferry ride from the city centre, Vallisaari Island offers visitors the chance to discover contemporary art amidst wild island nature, historic fortifications and panoramic views across the Baltic Sea. The experience continues in Esplanade Park, Helsinki’s iconic urban promenade, before leading visitors to HAM Helsinki Art Museum, one of Finland’s leading contemporary art institutions. United by the theme Unknowns, the fourth edition invites audiences to explore curiosity, imagination and the possibilities that emerge when we embrace what we do not yet understand.

For travellers seeking culture, design, architecture, food and nature in a single destination, Helsinki Biennial offers from 6 June to 19 September 2027 a compelling reason to visit the Finnish capital during its brightest and most vibrant season. 

International artists, new commissions and unexpected discoveries

Helsinki Biennial 2027 will bring together approximately 45 artists and artist groups from Finland and around the world. The first announced artists are Ari Bayuaji (Indonesia/Canada), Tara Donovan (United States), Laurent Grasso (France), Marguerite Humeau (France/United Kingdom), Matias Karsikas (Finland), Britta Marakatt-Labba (Sápmi/Sweden), Ragnhild May (Denmark), Yoshitomo Nara (Japan), Josefina Nelimarkka (Finland), Tawatchai Puntusawasdi (Thailand), Anna Retulainen (Finland) and Jakob Kudsk Steensen (Denmark). Further participants will be announced in the coming months.

Helsinki Biennial 2027 is curated by Mami Kataoka and Arja Miller. Photo: Kerttu Malinen, HAM / Helsinki Biennial

Exploring the Unknowns

Curated by Mami Kataoka and Arja Miller, Helsinki Biennial 2027 is built around the theme Unknowns. Rather than presenting clear answers, the biennial invites audiences to engage with mystery, wonder and uncertainty through art. Drawing inspiration from fields as diverse as astronomy, geology, science, mythology and spirituality, the biennial encourages visitors to imagine new ways of understanding both the visible and invisible worlds around us.

A proven success and a growing international attraction

With approximately 568,000 visits recorded in 2025, Helsinki Biennial has become one of the Nordic region’s leading contemporary art events and an increasingly important attraction for international visitors. Bringing together internationally acclaimed artists, cultural professionals, and audiences from around the world, the biennial offers a compelling reason to experience Helsinki in summer.

The event reflects what makes Helsinki unique: the opportunity to encounter contemporary art across a historic island, vibrant public spaces, and a leading art museum, all within easy reach of one another.

Alicja Kwade’s Big Be-Hide (2022) recalls the very first Helsinki Biennial, held in 2021.Photo: Maija Toivanen, HAM

Art that leaves a lasting mark on Helsinki

A visit to Helsinki Biennial offers more than a temporary exhibition experience. Several artworks commissioned for previous editions have become permanent additions to Helsinki’s public art collection, creating a growing cultural legacy across the city. For visitors, this means that each edition leaves a lasting mark on Helsinki, extending the experience well beyond the summer of the biennial itself.

Helsinki Biennial 2027
Unknowns
6 June – 19 September 2027
Vallisaari Island, Esplanade Park and HAM Helsinki Art Museum

Media Day
2 June 2027

Professional Preview Days
3 – 6 June 2027

www.helsinkibiennial.fi

More information
Leena Karppinen
Senior Manager, Brand & PR
Helsinki Partners
leena.karppinen@helsinkipartners.com  

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/helsinki-partners/r/why-helsinki-should-be-on-every-art-lover-s-travel-list-in-summer-2027,c4388986

The following files are available for download:

 

Lasfit Expands Its Vehicle-Specific Ford F-150 Upgrade Solutions Across Lighting, Protection and Outdoor Use

By
Advertorial Desk
-

LOS ANGELES, Aug. 28, 2026 /PRNewswire/ — Lasfit has rolled out brand-new LED ditch lights tailored for Ford F-150 off-road and outdoor adventures, further enriching its dedicated product ecosystem for the iconic pickup truck. This new launch adds a professional outdoor lighting option to Lasfit’s existing F-150 product portfolio, which already covers full-vehicle LED lighting upgrades and custom interior protection accessories.

Lasfit Vehicle-Specific Engineering: Better Fit, Improved Visibility and Enhanced Protection for Ford F-150 Owners
Lasfit Vehicle-Specific Engineering: Better Fit, Improved Visibility and Enhanced Protection for Ford F-150 Owners

Lasfit develops F-150 accessories based on each vehicle’s specific configuration and intended use. The process considers factors such as factory specifications, vehicle layout and real-world driving needs. Instead of manufacturing universal accessories first and making minor tweaks to fit different vehicles, the brand builds every product around the F-150 itself. Every design iteration takes into account the truck’s original factory specs, precise body dimensions, interior structural layout, reserved installation space, and real-world usage scenarios that F-150 drivers encounter daily. This vehicle-centric strategy now runs through all of Lasfit’s F-150 upgrades, ranging from daily driving lighting and interior floor protection to newly expanded off-road functional accessories.

Revamped F-150 Lighting Range Caters to Diverse Usage Scenarios

The newly released LED ditch lights are engineered specifically for F-150 owners who love trail exploration, camping, and all kinds of off-road activities, delivering reliable extra visibility for outdoor low-light environments. They complement Lasfit’s comprehensive F-150 LED lighting series, which already includes high/low beam headlights, fog lights, reverse lights, cargo lights, turn signals and other full-range exterior lighting upgrades, covering both daily road travel and outdoor operational lighting needs.

Many F-150 owners make the mistake of judging LED headlight quality solely by brightness. In reality, multiple key factors determine whether an LED bulb can perfectly match the truck, including the vehicle’s production year, original factory lighting configuration (halogen or stock LED), original bulb specifications, light source placement, headlight housing internal clearance, and heat dissipation performance. This explains why two seemingly identical F-150 trucks may require completely customized LED lighting solutions.

Lasfit’s Pro-DC Series LED headlights perfectly embody this customized development logic. Designed for F-150 models equipped with factory halogen headlights, the complete set features vehicle-exclusive LED bulbs paired with a custom extended dust cover. This tailored design maximizes the internal installation space of the original headlight housing, eliminating common installation barriers of generic bulbs.

Rather than simply providing standalone replacement bulbs, Lasfit integrates light source positioning, housing space matching, and professional thermal management into the overall product design. This proactive development method effectively avoids post-installation problems such as light scattering, glare, poor fitting and overheating, which are prevalent with universal LED upgrades. For F-150 drivers shopping for LED lighting upgrades, factory compatibility, precise fitment, scientific light source layout and stable heat control are just as critical as raw brightness output.

The new ditch light pack extends this professional, vehicle-first design concept to off-road scenarios. While its application shifts from daily on-road lighting to outdoor cross-country visibility assistance, the core development logic remains unchanged: start with the F-150’s inherent structural characteristics and actual usage demands, then create targeted accessory solutions.

All-Weather Floor Protection Matches Outdoor and Work Usage Needs

The harsh outdoor and working conditions that demand enhanced off-road lighting also take a toll on the F-150’s interior cabin. Daily commutes, muddy construction sites, wilderness camping and trail driving inevitably bring rainwater, mud, sand, dust and debris into the vehicle, making reliable interior floor protection an indispensable upgrade for F-150 owners.

Lasfit refuses to adopt a one-size-fits-all design for F-150 floor mats. It fully recognizes that F-150 models across different years come with varied cab styles, seat layouts, floor materials, rear under-seat storage structures and factory fixing buckles—all of which affect mat fitment and protection effect.

To achieve seamless full coverage, every set of Lasfit F-150 floor mats is developed based on precise 3D scanning of the actual vehicle interior. The mats are molded to fit every contour of the truck’s floor, with raised edge baffles and deep drainage grooves designed to trap all kinds of dirt and liquid, preventing stains from penetrating the original factory carpet.

Crafted from GRS-certified 100% recycled TPE material, these floor mats balance flexible foot feel with rugged all-weather durability. The waterproof, stain-resistant surface is extremely easy to clean—simply rinse with water and air dry to restore a brand-new state, ideal for work trucks and outdoor adventure vehicles. Meanwhile, reserved factory matching fixing points ensure the mats stay firmly in place during driving, avoiding sliding and displacement issues.

When selecting F-150 floor liners, drivers should prioritize vehicle-specific fit precision, full-area coverage, anti-slip fixation, material quality and dirt containment capacity, instead of blindly choosing universal mats based only on the vehicle model name. Authoritative automotive media evaluations have also verified the excellent real-world performance of Lasfit F-150 floor mats, praising their precise driver’s side fit, convenient cleaning and flexible durable material.

Consistent Custom Development Logic Across All F-150 Upgrades

LED lighting upgrades and floor protection accessories serve different functional purposes, yet they share Lasfit’s core development principle for the Ford F-150. For lighting products, the brand focuses on original lighting configuration, bulb specifications, housing structure and installation space; for floor mats, it centers on cab specifications, seat layout, floor structure and fixing design.

Though the core technical indicators vary by product category, the development starting point is always the same: analyze the unique configuration of each F-150 vehicle first, then develop exclusive accessories to match its characteristics. This targeted design approach is especially vital for the Ford F-150, as the same model name covers decades of iterations, multiple cab layouts, diverse interior configurations and different factory equipment packages.

Moreover, this design philosophy caters to the diverse usage scenarios of the F-150. As a multi-functional pickup, it seamlessly switches between daily commuting, heavy-duty work, family travel and outdoor off-roading, and Lasfit’s customized accessories can precisely meet the differentiated upgrade needs of each scenario.

Continuous Expansion of Lasfit’s Ford F-150 Product Ecosystem

Lasfit’s full lineup of Ford F-150 accessories keeps expanding, covering customized interior protection, multi-scenario LED lighting and professional outdoor off-road parts, fully covering every aspect of vehicle use and maintenance. Custom floor mats guard the interior cabin from daily dirt and outdoor abrasion, while the comprehensive LED lighting system solves visibility challenges for daily driving, outdoor activities and off-road use.

The new off-road ditch lights are not a directional shift for Lasfit’s F-150 product lineup, but an extension of its existing accessory offerings. The brand always adheres to its vehicle-customized development concept: take the vehicle’s inherent configuration as the foundation, combine real user usage habits, and create high-precision, high-adaptability and high-durability aftermarket accessories.

About Lasfit

Founded in 2015, Lasfit develops vehicle-specific automotive accessories for cars, trucks and SUVs. Based in Ontario, California, the brand offers custom-fit floor liners, LED lighting upgrades, truck protection products and off-road accessories designed for different vehicle configurations and driving environments. Through a focus on fitment, functionality and everyday practicality, Lasfit continues expanding its aftermarket solutions for vehicle owners.

InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation

By
Advertorial Desk
-

NANJING, China, Aug. 28, 2026 /PRNewswire/ — InxMed Co., Ltd (“InxMed”), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective focal adhesion kinase (FAK) inhibitor, in combination with garsorasib (D-1553), a potent KRAS G12C inhibitor, in previously treated KRAS G12C-mutant metastatic colorectal cancer (CRC), have been published online in The Lancet Oncology.

The data were derived from a phase Ib/II trial (NCT06166836/NCT05379946) evaluating the efficacy and safety of ifebemtinib plus garsorasib in KRAS G12C-mutant solid tumors, where ifebemtinib plus garsorasib, as an all-oral, chemotherapy-free regimen, demonstrated encouraging antitumor activity in patients with previously treated KRAS G12C-mutant metastatic CRC. This is the first clinical study, to our knowledge, to evaluate the efficacy and safety of FAK inhibitors in combination with KRAS G12C inhibitors in KRAS G12C-mutant solid tumors.

Encouraging Antitumor Efficacy and Manageable Safety Profile

The CRC cohort of this trial contains two parts: Part 1-single-arm study and Part 2-randomized study. In Part 1-single-arm study, 15 previously-treated KRAS G12C-mutant metastatic CRC patients were enrolled and received ifebemtinib (100mg once a day) plus garsorasib (600mg twice a day) orally. And in Part 2-randomized study, 36 previously-treated KRAS G12C-mutant metastatic CRC patients were enrolled and randomly assigned (1:1) to receive ifebemtinib plus garsorasib or garsorasib alone (600mg twice a day) orally. By the data cutoff on June 30, 2025, the median follow-up was 23.8 months in the single-arm study, and in the randomized study the median follow-up was 10•3 months for the combination group and 10•9 months for the monotherapy group. Key findings published in this paper were summarized below:

Objective Response Rate (ORR): In the single-arm study, 15 patients were enrolled with 14 patients evaluable, and the confirmed ORR was 46.7% (95% CI: 21.3–73.4) in the full population and 50.0% (95% CI: 23.0–77.0) in the evaluable population. In the randomized study, the confirmed ORR was 38.9% (95% CI: 17.3–64.3) in the ifebemtinib plus garsorasib group versus 16.7% (95% CI: 3.6–41.4) in the garsorasib monotherapy group, representing an absolute improvement of 22.2% in the combination group.

Progression-Free Survival (PFS): In the single-arm study, the median PFS was 6.9 months (95% CI: 2.8–12.0). In the randomized study, ifebemtinib plus garsorasib achieved a median PFS of 7.7 months (95% CI: 3.0–NE) versus 4.0 months (95% CI: 2.0–5.6) with garsorasib monotherapy group (HR 0.48, 95% CI: 0.22–1.04), pointing to a favorable PFS trend in favor of the combination.

Overall Survival (OS): In the single-arm study, the median OS was 14.3 months (95% CI: 4.7–NE). In the randomized study, the median OS was not estimable (95% CI: 10.2–NE) in ifebemtinib plus garsorasib group versus 7.5 months (95% CI: 5.3–NE) in garsorasib monotherapy group (HR 0.34, 95% CI: 0.11–1.12), suggesting a favorable OS trend in the combination group.

Manageable safety profile: Across all 33 patients receiving ifebemtinib plus garsorasib, 32 patients (97%) reported treatment-related adverse events (TRAE) with most of them reported as grade 1-2 and grade 3 TRAEs reported in 30% of patients. No grade 4 TRAEs, treatment-related deaths or TRAEs leading to study drug discontinuation were reported across all cohorts. The most common TRAEs occurring in all 33 patients receiving ifebemtinib plus garsorasib were diarrhoea, proteinuria, and nausea.

Overcoming Resistance by FAK Inhibition When Targeting KRAS

KRAS G12C mutations occur in approximately 3–4% of patients with metastatic colorectal cancer. Currently, KRAS G12C inhibitor monotherapy shows limited efficacy in this patient population, and two KRAS G12C inhibitors plus anti-EGFR antibody regimens demonstrated synergistic activity and have been approved by FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic CRC who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. However, anti-EGFR antibody requires intravenous administration and are commonly associated with dermatological toxicities. How to further enhance the efficacy of KRAS G12C-targeted therapy while providing a more convenient and tolerable treatment option has become a clinical imperative.

InxMed’s translational research found out that KRAS G12C inhibition alone triggers adaptive hyperactivation of the FAK–YAP signaling pathway, promotes fibrogenesis in the tumor microenvironment, and thereby enhances tumor cell survival. FAK inhibition by ifebemtinib disrupts this resistance mechanism, sensitizing tumor cells to KRAS G12C inhibition and prolonging the duration of treatment response. The clinical data reported herein provide further support for ifebemtinib in combination with KRAS G12C inhibitors in the treatment of previously treated KRAS G12C-mutant metastatic CRC.

Advancing the Clinical Development

The study demonstrates that the dual-oral, chemotherapy-free regimen of ifebemtinib plus garsorasib has shown encouraging antitumor activity and a manageable safety profile in patients with previously treated KRAS G12C-mutant metastatic CRC. These findings warrant a pivotal trial of this combination regimen to further establish its clinical benefit. The company has submitted an IND application in China, for a phase III trial evaluating the efficacy and safety of ifebemtinib plus garsorasib  versus investigators’ choice of standard therapy for treatment of previously treated metastatic colorectal cancer harboring KRAS G12C mutation.

Based on a robust translational medicine foundation and compelling clinical evidence, Ifebemtinib is poised to become a revolutionary therapeutic that could fundamentally reshape the RAS-targeted treatment paradigm. InxMed is strategically driving a comprehensive development program for Ifebemtinib across RAS-mutant tumors, with combination regimens already initiated or in preparation not only with KRAS G12C inhibitors, but also with KRAS G12D inhibitors and multi-RAS inhibitors, among other novel classes, underscoring the company’s commitment to transforming the future of RAS-addicted cancers.

About Ifebemtinib (IN10018)

Ifebemtinib (IN10018) is an orally available, highly potent, and selective small-molecule inhibitor of focal adhesion kinase (FAK). InxMed holds exclusive global development and commercialization rights. Clinically, ifebemtinib has demonstrated excellent safety and tolerability in over 700 subjects globally, showing vast potential as a “backbone” combination partner across multiple modalities, including RAS inhibitors, immune checkpoint blockades, and antibody-drug conjugates (ADCs). It has received multiple Breakthrough Therapy Designations from the NMPA and Fast Track Designation from the U.S. FDA.

About InxMed

Founded in 2017, InxMed is a late clinical-stage biotechnology company dedicated to tackling a central challenge in cancer therapy—drug resistance caused by tumor defense mechanisms. Our strategy focuses on critical signaling hubs shared across multiple tumor types, most notably the focal adhesion kinase (FAK) and integrin pathways, which play pivotal roles in tumor cell survival and contribute to treatment failure across various therapeutic modalities. In parallel, we target cancer-associated fibroblasts (CAFs) to dismantle the protective barrier around tumor cells. Through these integrated efforts, we aim to redefine cancer treatment and pioneer new frontiers in therapeutic innovation. For more information, please visit en.inxmed.com. 

 

Hizero Spells the End of the Vacuum Era With a Full Portfolio of No-Suction™ Hard-Surface Cleaners at IFA 2026

By
Advertorial Desk
-

Challenger brand introduces autonomous, powered, completely mechanical cleaners built around a fundamentally different approach to hard-surface cleaning.


BERLIN, GERMANY – Media OutReach Newswire – 28 August 2026 – The vacuum cleaner has dominated hard-surface cleaning centuries. Today Hizero is bringing that era to an end.

At IFA 2026, challenger cleaning brand is unveiling a full portfolio of No-Suction™ hard-surface cleaners that clean without conventional suction, vacuum motors, or high-speed airflow.

Rather than making vacuum cleaners more powerful, Hizero is taking the opposite approach: removing the vacuum altogether.

The company’s patented No Suction Technology replaces conventional airflow-based cleaning with bionic materials, direct-contact cleaning, water absorption, and mechanical waste separation.

At IFA, Hizero is demonstrating how far the concept can go with two new products: GLIDE, a no-suction robot cleaner, and EAZY, a fully mechanical cleaner that requires no battery, charging, or electronic motor.

Together with Hizero’s existing hard-surface cleaning products, they represent the company’s ambition to establish No-Suction as a new category of cleaning.

The Vacuum Era Is Ending

For generations, the basic principle of floor cleaning has remained unchanged: use suction to lift, transport and collect dirt.

Even today’s wet-and-dry cleaners continue to rely on the same architecture, combining a powerful motor, high-speed airflow and a roller or wiping system.

Hizero challenges that assumption.

Its No-Suction approach is based on a simple proposition: hard surfaces can be cleaned without needing a vacuum.

At the heart of the system is Hizero’s proprietary bionic polymer Multi Roller. Rather than relying on suction to pull debris from the surface, the roller makes direct contact with the floor, capturing solid debris while absorbing liquid.

As it moves, the roller is continuously refreshed with clean water. An integrated scraper removes dirty water, while the cleaning system separates different types of waste.

The result is a fundamentally different cleaning architecture:

  • No suction.
  • No vacuum motor.
  • No conventional exhaust airflow.

Instead, Hizero uses material science and mechanical engineering to do the work traditionally assigned to a vacuum motor.

No-Suction™ Goes Autonomous: Meet GLIDE

The Hizero GLIDE takes No-Suction technology to robot floor cleaning.

GLIDE combines app-directed navigation with Hizero’s No Suction Technology, allowing it to clean hard floors without relying on conventional vacuum suction.

Its polymer Multi Roller captures dry debris and absorbs liquid while being continuously rinsed during operation.

GLIDE also incorporates Triple Auto Waste Separation, which separates solid debris, liquid waste, and hair inside the machine.

That means the cleaning process is not simply about moving dirt into a container. The machine actively manages multiple waste streams as it cleans.

For consumers, GLIDE provides hard-floor cleaning with a smartphone tap.

For the appliance industry, its significance is more fundamental:

GLIDE is a robotic cleaner that eliminates the need for vacuuming.

No-Suction™ Without Power: Meet EAZY

At the opposite end of the technology spectrum is Hizero EAZY — demonstrating that No-Suction™ cleaning does not necessarily require any technology at all.

EAZY operates without a battery, charging system, or electronic motor.

A simple push-pull motion drives the cleaning process. A squeeze trigger dispenses clean water onto the polymer roller, which captures debris and absorbs liquid as it moves across the surface.

The internal mechanism separates solid waste from dirty water.

In a single continuous action, EAZY is designed to sweep, wash, and wipe hard surfaces.

  • There is no motor to charge.
  • No battery to replace.
  • No vacuum to power.

Just mechanical cleaning.

The result is a remarkably simple approach with applications ranging from kitchens, patios and homes to commercial environments.

One Technology. A Growing No-Suction™ Ecosystem.

GLIDE and EAZY are not standalone experiments. The company’s portfolio now spans autonomous floor care, powered hard-surface cleaning, handheld applications, and purely mechanical cleaning.

Hizero’s bionic technology has also been evolved for applications beyond floors, including countertops, windows, mirrors, and other hard surfaces, with opportunities across residential, hospitality, and commercial environments.

Rather than competing to build the most powerful vacuum, Hizero is challenging the industry to consider whether a vacuum is even necessary.

Challenging the Cleaning Status Quo

“For more than a century, the industry has focused on making vacuum cleaning better,” said Sam Li, Founder and CEO of Hizero. “We decided to challenge the assumption behind it. What if you don’t need the vacuum at all? No-Suction™ is our answer. We believe hard-surface cleaning is ready for a fundamentally different approach.”

At IFA 2026, Hizero is inviting the appliance industry — and consumers — to look beyond suction.

Because the next generation of hard-surface cleaning may not be about more suction, more noisy power, or more complexity.

“We welcome people and businesses to a new future of no suction cleaning, which heralds the end of vacuuming as we know it,” says Sam Li.

Hashtag: #Hizero

The issuer is solely responsible for the content of this announcement.

ONE OR EIGHT Set to Ignite Southeast Asia with “Special SHOW CASE 2026 in ASIA -V8-” This October

By
Advertorial Desk
-

Rising Japanese boy group brings its high-energy live showcase to Singapore, Manila and Bangkok

Three-city Southeast Asia run follows growing global momentum, with tickets on sale from 31 August 2026

SINGAPORE – Media OutReach Newswire – 28 August 2026 – Rising Japanese boy group ONE OR EIGHT is set to bring its rapidly growing global momentum to Southeast Asia with ONE OR EIGHT Special SHOW CASE 2026 in ASIA -V8-, a three-city showcase taking place in Singapore, Manila and Bangkok this October.

OOE KV launchDate

Following the group’s first-ever ONE OR EIGHT 1st LIVE TOUR -GATHER-, which took ONE OR EIGHT across North and South America, the upcoming showcase marks the group’s next major step in connecting directly with fans across Asia. The tour will kick off in Singapore on 21 October 2026 at Victoria Theatre, before heading to Manila on 23 October at Samsung Hall, SM Aura Premier, and conclude in Bangkok on 25 October at Lido Hall 2, Lido Connect.

Ticket sales will begin from 31 August 2026 onwards, with more details via oneoreight.sozolive.asia

One of Japan’s emerging global acts comes to Southeast Asia

ONE OR EIGHT comprises eight members — MIZUKI, NEO, REIA, RYOTA, SOUMA, TAKERU, TSUBASA and YUGA.

The group’s name is derived from the Japanese idiom “ichi ka bachi ka”, which expresses the idea of taking an all-or-nothing gamble. Together with their tagline “BET ON YOURSELF”, the name reflects the members’ determination to pursue their dreams, challenge boundaries and take their music to audiences around the world.

Since making their debut in August 2024, ONE OR EIGHT have quickly established themselves as one of Japan’s emerging global acts.

Their track “TOKYO DRIFT” generated more than 200,000 pieces of user-generated content on TikTok and over 300 million views, while also entering the Mediabase Top 40 and setting a record for the most chart entries by a Japanese boy group.

Their growing recognition has extended across Asia. ONE OR EIGHT received the Upcoming Dance & Vocal Group award at the MTV VMAJ 2025 in Japan and was named New Artist of the Year at the 2025 Music Awards organised by China’s NetEase. The group has also worked with internationally acclaimed creators including Ryan Tedder, David Stewart and Big Sean, further strengthening its ambitions to connect Japanese music with a global audience.

A NEW CHAPTER WITH “EN-GiNE”

Ahead of their Southeast Asia showcases, ONE OR EIGHT will release their first EP, “EN-GiNE”, on 16 September 2026. The title combines the Japanese word “EN” (縁), representing connection and fate, with “GENE”, symbolising the new driving force created through the relationships the members have developed with one another and with fans around the world. Following “YANKEE SQUAT”, the group recently released “INVINCIBLE”, the second single from the upcoming EP.

Dedicated to their fans, known as 1DERZ, “INVINCIBLE” carries the message that no journey is taken alone, celebrating the trust, gratitude and connection that have grown between ONE OR EIGHT and their supporters since their debut.

With Special SHOW CASE 2026 in ASIA -V8-, fans in Southeast Asia will now have the opportunity to experience that connection in person.

TOUR INFORMATION

SINGAPORE

Wednesday, 21 October 2026
Victoria Theatre
Doors: 7:00 PM
Show: 7:30 PM

Tickets

  • VVIP Seated: SGD 138
  • VIP Seated: SGD 108
  • GA Seated: SGD 88

Tickets go on sale from 31 August 2026 at 12:00 PM Singapore Time via Ticketmaster Singapore.

MANILA

Friday, 23 October 2026
Samsung Hall, SM Aura Premier
Doors: 7:00 PM
Show: 8:00 PM

Tickets

  • VVIP Standing: PHP 4,500
  • VIP Standing: PHP 3,500
  • GA Standing: PHP 2,500

Tickets go on sale from 31 August 2026 at 12:00 PM Manila Time via Ticketmaster Philippines.

BANGKOK

Sunday, 25 October 2026
Lido Hall 2, Lido Connect
Doors: 5:00 PM
Show: 6:00 PM

Tickets

  • VVIP Standing: THB 3,000
  • VIP Standing: THB 2,500
  • GA Standing: THB 1,500

Tickets go on sale from 31 August 2026 at 11:00 AM Bangkok Time via SOZOLIVE Ticketing.

VVIP EXPERIENCE

Across all three cities, the top-tier VVIP package gives fans an opportunity to get even closer to ONE OR EIGHT, with benefits including:

  • Best-view section closest to the stage
  • 1-for-all photo session with ONE OR EIGHT
  • Soundcheck access
  • Signed poster
  • Exclusive VVIP badge and lanyard
  • Priority concert admission

VIP ticket holders will also receive a signed poster, VIP badge and lanyard, and priority admission.

Three cities. One special showcase. Southeast Asia, are you ready for ONE OR EIGHT?

For complete event, ticketing and entitlement information, visit oneoreight.sozolive.asia

Hashtag: #ONEOREIGHT #ONEOREIGHT_V8 #ONEOREIGHTAsia #SOZOLIVE

The issuer is solely responsible for the content of this announcement.

ABOUT SOZO

Established in 2009 and headquartered in Singapore, SOZO Pte Ltd, a KADOKAWA Group company, is a leading entertainment company connecting Japanese entertainment with audiences across Southeast Asia.

Through its flagship platform, Anime Festival Asia (AFA), SOZO pioneered the region’s Anime, Comics and Games scene and built one of Southeast Asia’s most recognised Japanese pop-culture event brands.

Beyond conventions, SOZO produces major live entertainment experiences for leading Japanese artists including Ado, Eve, RADWIMPS, YOASOBI and Yuuri. The company also provides merchandise production, retail and regional distribution solutions, creating powerful platforms for Japanese artists, creators and intellectual properties to reach and engage fans across the region.

Bringing Japanese Entertainment to the World.

Singapore fintech investment moderates in H1 2026 as capital concentrates in fewer, larger deals: Pulse of Fintech H1 2026

By
Advertorial Desk
-
SINGAPORE – Media OutReach Newswire – 28 August 2026 – Singapore’s fintech sector drew over US$499 million in investment across 53 deals in the first half of 2026, according to KPMG’s Pulse of Fintech H1’2026 report. This marks a drop from the roughly US$1.45 billion across 97 deals recorded in H1 2025. It also represents the most subdued first half the country saw in about close to a decade.

The moderation was uneven across the half. After a notably quiet first quarter of about US$88 million across 26 deals, activity rebounded to some US$411 million across 27 deals in the second quarter. That recovery rested almost entirely on a single US$320 million round for a cross-border payments platform in June, which alone accounted for close to two-thirds of Singapore’s total fintech investment for the half.

Anton Ruddenklau, Partner, Head of Financial Services, KPMG in Singapore said: “The headline number tells only part of the story. What we are seeing in Singapore mirrors the global market — investors are being far more selective, consolidating capital behind a small number of scaled, high-conviction platforms rather than funding behaviour we saw in prior years. A single deal carrying most of the half is a signal of that concentration. However, the fundamentals that make Singapore a strategic hub for fintech — a trusted regulatory environment, deep cross-border connectivity, and strength in payments and digital assets — remain intact, and these remain the stronghold areas where capital is still flowing.”

Investment clustered around three familiar verticals: payments, digital assets and cryptocurrency, and artificial intelligence and machine learning. Most investments clustered towards earlier-stage companies building tokenisation, digital-asset and AI-enabled infrastructure, pointing to a market that is still forming at the foundations even as growth-stage funding thins.

Globally, the picture ran in the opposite direction on value. Fintech investment across venture capital, private equity and M&A rose from US$72.2 billion in H2’25 to US$103.1 billion in H1’26, putting the sector on pace for its strongest annual performance in four years. Deal volume, however, remained soft at just 2,100 deals globally in H1’26 against 2,500 in H2’25, as investors concentrated capital on large transactions centred on mature fintechs with well-proven business models. Singapore’s half was a local expression of that same dynamic, fewer deals, larger concentration, and a clear premium on proven models.

Figure 1: Singapore’s half-year fintech deal value and volume, H1 2019 – H1 2026

Period Deal value (US$M) No. of deals
H1 2019 610 85
H1 2020 578 100
H1 2021 1,234 170
H1 2022 3,540 234
H1 2023 1,609 126
H1 2024 624 155
H1 2025 1,449 97
H1 2026 499 53

Source: KPMG Pulse of Fintech, PitchBook.

Figure 2: Singapore fintech investment by vertical, H1 2026

Vertical No. of deals Disclosed deal value (US$M)
Artificial intelligence & machine learning 18 365.9
Payments 3 332.0
Cryptocurrency / blockchain 27 95.5
RegTech 2 19.1
ESG / greentech 1 14.0
InsurTech 4 12.3
WealthTech 1 —
PropTech 0 —
Cybersecurity 0 —

*Deals are frequently tagged to more than one vertical

Payments remains one of Singapore’s anchor verticals

Cross-border payments proved to be one of Singapore’s anchor verticals, although it was largely supported by a US$320 million deal in June. That single transaction accounted for nearly all of the US$332 million recorded across the three payments deals in the half. Two of the three deals belonging to the later stage even in a tighter funding climate reflects sustained investor appetite for scaled platforms that can move money across borders while managing compliance, currency conversion and settlement – capabilities that only grow more valuable as global trade and commerce fragment.

Digital assets and cryptocurrency continue to drive deal activity

Digital assets and cryptocurrency again accounted for the largest share of Singapore’s deal count, even if individual cheque sizes were relatively modest. The larger, later-stage names were built around regulated market infrastructure, including companies such as digital-asset services providers and crypto payments firms, while the seed and early-stage cohort skewed towards exchange, brokerage and cross-chain tooling platforms. With most capital concentrated at seed and early stage (15 of the 27 deals) rather than in large growth rounds, it signals continued confidence in Singapore as a base for regulated, institutional-grade digital-asset businesses, even as the sector’s weight in the market rests on young companies rather than proven, scaled platforms.

AI and machine learning stays central to the fintech thesis

Artificial intelligence and machine learning was the most active vertical of the half, featuring in 18 of Singapore’s 53 deals and US$365.9 million of disclosed value. The deals were split equally across early and late stage deals.

The later-stage deals clustered around applied software that embeds AI into established financial workflows, spanning cross-border payments, investment research, insurance and claims, credit-risk modelling and document processing. These are revenue-generating platforms using AI to improve productivity and margins rather than to build entirely new markets, which is why they continued to attract the larger capital even in a more selective climate, as investors are willing to pay up for proven models where AI deepens an existing commercial edge.

At seed and early stage, the profile shifts towards agentic software and infrastructure, including agentic execution platforms, agentic networks and cross-chain automation, alongside broader AI-and-crypto tooling. This could signal that investors are expecting that autonomous, AI-driven agents may become core infrastructure for how money moves and how financial decisions are executed.

2026 – Key Global highlights

  • Global fintech investment has grown considerably over the past three six-month periods, rising from $50.5 billion in H1’25 to $72.2 billion in H2’25 to $103.1 billion in H1’26.
  • Global deal volume fell from 2,500 deals in H2’25 to 2,100 in H1’26; this remains below historic norms, reflecting continued investor selectivity despite higher capital deployment.
  • The Americas attracted over 80 percent of global fintech investment in H1’26 ($86.9 billion across 1,120 deals), of which the US accounted for $80.8 billion across 933 deals.
  • Coming off a strong 2025 that saw $39.5 billion invested across 1,714 deals, the EMEA region saw $11.3 billion invested across 626 deals in H1’26 – on pace for a decade-low for both deal volume and value.
  • Fintech investment in the ASPAC region remained muted, declining from $7.1 billion across 426 deals during H2’25 to $4.6 billion across 350 deals in H1’26.
  • Global fintech M&A activity strengthened, with deal value increasing from $37.2 billion across 514 deals in H2’25 to $67.9 billion across 394 deals in H1’26
  • Venture capital investment remained strong across the global fintech sector, led by the US which saw $16.8 billion in VC investment.
  • At the sector level, payments led the way, attracting $44.2 billion in H1’26: well over 2025’s annual total, as a result of several large megadeals.
  • AI-focused fintechs attract $21.4 billion across VC, PE, and M&A.

Hashtag: #KPMG

The issuer is solely responsible for the content of this announcement.

About KPMG International

KPMG is a global organization of independent professional services firms providing Audit, Tax and Advisory services. KPMG is the brand under which the member firms of KPMG International Limited (“KPMG International”) operate and provide professional services. “KPMG” is used to refer to individual member firms within the KPMG organization or to one or more member firms collectively.

KPMG firms operate in 138 countries and territories with more than 276,000 partners and employees working in member firms around the world. Each KPMG firm is a legally distinct and separate entity and describes itself as such. Each KPMG member firm is responsible for its own obligations and liabilities.

KPMG International Limited is a private English company limited by guarantee. KPMG International Limited and its related entities do not provide services to clients. For more detail about our structure, please visit kpmg.com/governance.

1...146147148...6,609Page 147 of 6,609